Gyre Therapeutics (NASDAQ:GYRE) Shares Up 3.7%

Gyre Therapeutics, Inc. (NASDAQ:GYREGet Free Report)’s share price shot up 3.7% on Friday . The company traded as high as $12.15 and last traded at $12.15. 4,004 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 80,032 shares. The stock had previously closed at $11.72.

Gyre Therapeutics Stock Up 6.1 %

The business’s 50 day moving average is $12.43 and its two-hundred day moving average is $16.43.

Gyre Therapeutics (NASDAQ:GYREGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.04 EPS for the quarter. The firm had revenue of $27.17 million during the quarter. As a group, equities analysts predict that Gyre Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Gyre Therapeutics

In other Gyre Therapeutics news, Director Nassim Usman sold 20,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $14.13, for a total value of $282,600.00. Following the completion of the transaction, the director now directly owns 1,636 shares of the company’s stock, valued at approximately $23,116.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 2.92% of the company’s stock.

Gyre Therapeutics Company Profile

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.

Featured Stories

Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with's FREE daily email newsletter.